North America Women’s Health Market Size & Outlook
North America women’s health market, 2018-2030 (US$M)
Related Markets
North America women’s health market highlights
- The North America women’s health market generated a revenue of USD 18,384.6 million in 2023.
- The market is expected to grow at a CAGR of 5.1% from 2024 to 2030.
- In terms of segment, contraceptives was the largest revenue generating application in 2023.
- Endometriosis & Uterine Fibroids is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Canada is expected to register the highest CAGR from 2024 to 2030.
North America data book summary
| Market revenue in 2023 | USD 18,384.6 million |
| Market revenue in 2030 | USD 26,084.7 million |
| Growth rate | 5.1% (CAGR from 2023 to 2030) |
| Largest segment | Contraceptives |
| Fastest growing segment | Endometriosis & Uterine Fibroids |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Hormonal Infertility, Contraceptives, Postmenopausal Osteoporosis, Endometriosis & Uterine Fibroids, Menopause, Polycystic Ovary Syndrome (PCOS) |
| Key market players worldwide | AbbVie Inc, Bayer AG, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Agile Therapeutics Inc, Amgen Inc, Apothecus, Blairex Laboratories, Ferring |
Other key industry trends
- In terms of revenue, North America region accounted for 41.4% of the global women’s health market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 17,433.6 million by 2030.
Contraceptives was the largest segment with a revenue share of 35.38% in 2023. Horizon Databook has segmented the North America women’s health market based on hormonal infertility, contraceptives, postmenopausal osteoporosis, endometriosis & uterine fibroids, menopause, polycystic ovary syndrome (pcos) covering the revenue growth of each sub-segment from 2018 to 2030.
Increase in the population of older women in the region is one of the key factors driving the demand for women’s health products in North America. More than 15% of the women in North America are above the age of 65 years.
Moreover, increasing prevalence of osteoporosis in postmenopausal women is a key factor expected to drive the demand for women’s health products, including drugs and devices. Increase in the number of market approvals of women’s health drugs and high healthcare expenditure are among the factors contributing to market growth.
For instance, in May 2023, the U.S. FDA approved Veozah (fezolinetant) to reduce the frequency and severity of hot flashes in menopause. Moreover, in May 2020, AbbVie’s Oriahnn received FDA approval. It is an oral medication indicated for heavy menstrual bleeding due to uterine fibroids.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Women’s Health Market Scope
Women’s Health Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America women’s health market size, by country, 2018-2030 (US$M)
North America Women’s Health Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
